Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provide… Read more
Zhejiang Dayang Biotech Group Co (003017) - Total Assets
Latest total assets as of September 2025: CN¥1.75 Billion CNY
Based on the latest financial reports, Zhejiang Dayang Biotech Group Co (003017) holds total assets worth CN¥1.75 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Dayang Biotech Group Co - Total Assets Trend (2013–2024)
This chart illustrates how Zhejiang Dayang Biotech Group Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhejiang Dayang Biotech Group Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Dayang Biotech Group Co's total assets of CN¥1.75 Billion consist of 41.8% current assets and 58.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 21.4% |
| Accounts Receivable | CN¥128.33 Million | 7.8% |
| Inventory | CN¥119.78 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥91.06 Million | 5.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Zhejiang Dayang Biotech Group Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Dayang Biotech Group Co's current assets represent 41.8% of total assets in 2024, a decrease from 52.6% in 2013.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2024, up from 12.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 6.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 7.8% of total assets.
Zhejiang Dayang Biotech Group Co Competitors by Total Assets
Key competitors of Zhejiang Dayang Biotech Group Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dawood Hercules Corporation Ltd
KAR:DAWH
|
Pakistan | PKRs781.72 Billion |
|
Fauji Fertilizer Bin Qasim Ltd
KAR:FFBL
|
Pakistan | PKRs203.28 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥24.47 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
China | CN¥212.80 Billion |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
China | CN¥2.53 Billion |
|
Jilin Gpro Titanium Industry Co Ltd
SHE:000545
|
China | CN¥2.48 Billion |
|
Aoyuan Beauty Valley Technology Co Ltd
SHE:000615
|
China | CN¥2.74 Billion |
Zhejiang Dayang Biotech Group Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Zhejiang Dayang Biotech Group Co generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Zhejiang Dayang Biotech Group Co generates $ 3.86 in net profit.
Zhejiang Dayang Biotech Group Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 1.21 | 3.48 |
| Quick Ratio | 1.03 | 0.97 | 3.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥136.82 Million | CN¥ 117.25 Million | CN¥ 497.78 Million |
Zhejiang Dayang Biotech Group Co - Advanced Valuation Insights
This section examines the relationship between Zhejiang Dayang Biotech Group Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | CN¥1.65 Billion |
| Market Capitalization | $215.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Dayang Biotech Group Co's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Dayang Biotech Group Co's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Dayang Biotech Group Co (2013–2024)
The table below shows the annual total assets of Zhejiang Dayang Biotech Group Co from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion | +6.91% |
| 2023-12-31 | CN¥1.55 Billion | +2.57% |
| 2022-12-31 | CN¥1.51 Billion | +9.72% |
| 2021-12-31 | CN¥1.37 Billion | +11.84% |
| 2020-12-31 | CN¥1.23 Billion | +90.33% |
| 2019-12-31 | CN¥645.60 Million | +7.31% |
| 2018-12-31 | CN¥601.61 Million | +17.25% |
| 2017-12-31 | CN¥513.08 Million | +9.93% |
| 2016-12-31 | CN¥466.72 Million | +1.71% |
| 2015-12-31 | CN¥458.88 Million | -0.95% |
| 2014-12-31 | CN¥463.30 Million | +4.97% |
| 2013-12-31 | CN¥441.35 Million | -- |